Idenix up premarket

Shares of Idenix Pharmaceuticals (IDIX) are up almost 17% premarket on no significant news.

Consensus revenue estimates for 2014 and 2015 are $1.5M and $7.7M, respectively.

175 mutual funds have positions, down from 198 a year earlier.

Three analysts rate the company at least Buy, eight rate it Hold, two rate it Underperform and one rates it Sell.

Comments (1)
  • bppalmer
    , contributor
    Comments (2) | Send Message
    Q1. How did you come up with 17%
    Q2. Why not also mention that the premarket increase was on 600 share volume?
    10 Mar 2014, 09:47 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs